Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Melanoma 12Carcinoma, Renal Cell 11Lymphoma 3Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Colorectal Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Margins of Excision 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1HTLV-I Infections 1Carcinoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Adenocarcinoma 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 9Mycophenolic Acid 9Cyclophosphamide 8Busulfan 8Tacrolimus 7Cyclosporine 5ruxolitinib 4fludarabine 4Methotrexate 4Antilymphocyte Serum 411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2Stem Cell Transplantation 2Radiotherapy 2Melphalan 2Etoposide 2Carboplatin 2veliparib 1thymoglobulin 1sonidegib 1pomalidomide 1merphos 1bomedemstat 1anagrelide 1Transplantation 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thrombocythemia, Essential × Interferon alpha-2 × Clear all
NCT00452023 2024-12-11

Pegasys® in Patients With Myeloproliferative Diseases

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 12 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡